Press release from Companies
Publicerat: 2022-09-04 22:40:50
COPENHAGEN – Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS). The Company’s managerial employee have given Curasight power of attorney on her behalf to publish purchase of Curasight shares as managerial employee conducted the 1 September 2022.
The transaction comprises the following managerial employee;
| Name | Position | Aggregated volume | Price, DKK |
| Hanne Damgaard Jensen | Chief Development Officer | 7.600 | 97.964 |
| Total | 7,600 | 97.964 |
Hanne Damgaard Jensen total holdings in Curasight A/S after the purchase of the shares is 35,000 shares.
For further information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology provides improved diagnosis and risk stratification in multiple cancer types.
